kl 1

SEC inhibitor KL-1 (KL-1) is a potent, selective super elongation complex (SEC) inhibitor that exhibits a dose-dependent inhibitory effect on AFF4-CCNT1 interaction (Ki: 3.48 μM) and disrupts the interaction between the SEC scaffolding protein AFF4.

Panomifene TFA(GYKl13504 TFA) is a small molecule antagonist of ERs with anticancer activity that can be used to study breast cancer and musculoskeletal diseases.

KL1333 (NQO1 activator 1) enhances energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. Elevated NAD+ levels trigger the activation of SIRT1 and AMPK, and subsequently activates PGC-1α. NQO1 activator 1 is an orally available NAD+ modulator. It reacts with NAD(P)H: NQO1 as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation.

ZX-29 is a potent and selective inhibitor of ALK with IC50 values of 2.1 nM, 1.3 nM, and 3.9 nM for ALK, ALK [L1196M], and ALK [G1202R] mutations, respectively. It also induces protective autophagy and exhibits antitumor effects.

KL101 is a novel CRY1 stabilizer with selective action.

KL1333 hydrochloride is an orally effective NAD+ modulator that acts as a substrate for NAD(P)H: quinone oxidoreductase 1 (NQO1), leading to increased intracellular NAD+ levels through NADH oxidation. Elevated NAD+ subsequently activates SIRT1 and AMPK, which in turn activate PGC-1α. KL1333 hydrochloride improves energy metabolism and mitochondrial dysfunction in fibroblasts of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). It also has a protective effect against cisplatin-induced ototoxicity in cultured mouse cochlea.

KL-1156 is an NF-κB inhibitor. It is also a lipopolysaccharide (LPS)-induced nitric oxide production inhibitor.

YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor.

KKL-10, a ribosome rescue inhibitor, has broad-spectrum antimicrobial activity against bacteria.

CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. This compound also inhibits PC-3 cell migration (IC50: 4.2 μM), as determined by a scratch wound assay. CCG-203971(CCG203971) causes no cytotoxicity when evaluated by the WST-1 assay. It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days.

KL-11743 specifically blocks glucose metabolism, triggering an acute collapse in NADH pools and a striking accumulation of aspartate, indicating a dramatic shift toward oxidative phosphorylation in the mitochondria.

Endogenous human tachykinin-like peptide and potent agonist for NK1 receptors (EC50 = 1 nM).

potent agonist for NK1 receptors

C14TKL-1 acetate is a NK1 receptor agonist.

Biperiden Hydrochloride (KL 373 Hydrochloride) is an anticholinergic antiparkinsonian agent that selectively blocks central M1 cholinoreceptors while exerting atropine-like effects on peripheral parasympathetic structures. Biperiden Hydrochloride is approved for the adjunctive treatment of postencephalitic, idiopathic, and arteriosclerotic Parkinson’s disease, demonstrates minimal impairment of novelty preference compared with other anticholinergics in comparative cognitive studies, and is associated with known adverse effects including drowsiness, vertigo, headache, and dizziness.

Tagitanlimab (HBM-9167; KL-A167) is a humanized monoclonal antibody targeting PD-L1 that selectively blocks PD-L1-PD-1 interactions. It can be used to study recurrent or metastatic nasopharyngeal carcinoma (NPC).